Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Alberto Fajardo

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|July 12, 2019
Determinants for Neoantigen IdentificationAndrea Garcia-Garijo, Carlos Alberto Fajardo, Alena Gros
Cancer Gene Therapy|June 18, 2019
Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriersPaula Barlabé, Jana de Sostoa, Carlos Alberto Fajardo, et al.
Human Gene Therapy|March 4, 2014
Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the fieldDragomira Majhen, Hugo Calderon, Naresh Chandra, et al.
Journal for Immunotherapy of Cancer|January 27, 2019
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engagerJana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 9, 2016
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic deliveryLuis Alfonso Rojas, Gabriela N Condezo, Rafael Moreno, et al.
World Journal of Gastrointestinal Oncology|May 15, 2013
CagA EPIYA polymorphisms in Colombian Helicobacter pylori strains and their influence on disease-associated cellular responsesCarlos Alberto Fajardo, Andrés Javier Quiroga, Andrea Coronado, et al.
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
Molecular Therapy Oncolytics|June 12, 2018
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic AdenovirusAhmed Abdullah Al-Zaher, Rafael Moreno, Carlos Alberto Fajardo, et al.
Cancer Immunology Research|March 29, 2018
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell EngagerAnna Wing, Carlos Alberto Fajardo, Avery D Posey, et al.
Molecular Cancer Therapeutics|October 17, 2018
Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear CellsRafael Moreno, Carlos Alberto Fajardo, Marti Farrera-Sal, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|July 12, 2019
Determinants for Neoantigen IdentificationAndrea Garcia-Garijo, Carlos Alberto Fajardo, Alena Gros
Cancer Gene Therapy|June 18, 2019
Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriersPaula Barlabé, Jana de Sostoa, Carlos Alberto Fajardo, et al.
Human Gene Therapy|March 4, 2014
Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the fieldDragomira Majhen, Hugo Calderon, Naresh Chandra, et al.
Journal for Immunotherapy of Cancer|January 27, 2019
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engagerJana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 9, 2016
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic deliveryLuis Alfonso Rojas, Gabriela N Condezo, Rafael Moreno, et al.
World Journal of Gastrointestinal Oncology|May 15, 2013
CagA EPIYA polymorphisms in Colombian Helicobacter pylori strains and their influence on disease-associated cellular responsesCarlos Alberto Fajardo, Andrés Javier Quiroga, Andrea Coronado, et al.
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
Molecular Therapy Oncolytics|June 12, 2018
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic AdenovirusAhmed Abdullah Al-Zaher, Rafael Moreno, Carlos Alberto Fajardo, et al.
Cancer Immunology Research|March 29, 2018
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell EngagerAnna Wing, Carlos Alberto Fajardo, Avery D Posey, et al.
Molecular Cancer Therapeutics|October 17, 2018
Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear CellsRafael Moreno, Carlos Alberto Fajardo, Marti Farrera-Sal, et al.
Pageof 2